VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement

Transactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs) Support Closing of Business Combination with Voyager Acquisition Corp. ZURICH, SWITZERLAND - May 28, 2026 - VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that it has strengthened its financial position to support the closing of its business combination with Voyager Acquisition Corp.